Platt L, French CE, McGowan CR, et al. - Via performing a systematic review, researchers sought to determine the global burden of HBV co-infection (HBsAg positive) among people are living with HIV (PLHIV). Searching MEDLINE, EMBASE and other databases (2002-2018), they assessed 506 estimates (475 studies) of HIV-HBsAg co-infection prevalence from 80/195 (41.0%) countries. Globally, HIV-HBsAg co-infection is prevalent in 6.1% (IQR 4.0-9.9%) among PLHIV, or there are 2.6 million HIV-HBsAg co-infections (IQR 1.9-4.2). Sub-Saharan Africa exhibited the greatest burden (69% of cases; 1.9 million). Globally, the population groups displayed only little difference in prevalence of HIV-HBsAg co-infection (approximately 6-7%); but this was slightly higher among PWID (11.8% IQR 6. 0-16.9%). PLHIV relative to HIV-negative individuals had 1.4 times higher odds of HBsAg infection. Findings emphasize the significance of specifically targeting PLHIV for testing, catch-up HBV vaccination and other preventative interventions. An increase in the use of a tenofovir-based ART regimen for treating HIV among PLHIV affords an opportunity to concurrently treat those with HBsAg co-infection and decrease mother-to-child transmission of HBV alongside HIV.